Drug intelligence / Profile preview

CCT-102

Development stage: Unknown
Lead developer: Conceptra Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**CCT-102** is an investigational two-component oral drug regimen developed by Conceptra Biosciences for uterine evacuation following first-trimester delayed pregnancy loss, including anembryonic pregnancy and embryonic demise. The regimen consists of two sponsor-designated components, CCT-102 A and CCT-102 B, administered over two days. Its individual active pharmaceutical ingredients and their precise mechanisms have not been publicly identified in the registered trial record.

Other names: Simultaneous mifepristone and buccal misoprostol

Targets

PR (Progesterone receptor)PTGER (Prostaglandin E2 receptor)AR (Adrenergic receptors)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on CCT-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCT-102.

Explore the full profile